Logo image of MNOV

MEDICINOVA INC (MNOV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MNOV - US58468P2065 - Common Stock

1.54 USD
+0.03 (+1.99%)
Last: 12/12/2025, 2:04:47 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNOV. MNOV was compared to 531 industry peers in the Biotechnology industry. MNOV has a great financial health rating, but its profitability evaluates not so good. MNOV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MNOV had negative earnings in the past year.
MNOV had a negative operating cash flow in the past year.
MNOV had negative earnings in each of the past 5 years.
In the past 5 years MNOV always reported negative operating cash flow.
MNOV Yearly Net Income VS EBIT VS OCF VS FCFMNOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

MNOV's Return On Assets of -23.22% is fine compared to the rest of the industry. MNOV outperforms 72.69% of its industry peers.
Looking at the Return On Equity, with a value of -25.13%, MNOV is in the better half of the industry, outperforming 79.47% of the companies in the same industry.
Industry RankSector Rank
ROA -23.22%
ROE -25.13%
ROIC N/A
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
MNOV Yearly ROA, ROE, ROICMNOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNOV Yearly Profit, Operating, Gross MarginsMNOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

MNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MNOV remains at a similar level compared to 1 year ago.
The number of shares outstanding for MNOV has been increased compared to 5 years ago.
There is no outstanding debt for MNOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNOV Yearly Shares OutstandingMNOV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MNOV Yearly Total Debt VS Total AssetsMNOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.66, we must say that MNOV is in the distress zone and has some risk of bankruptcy.
MNOV has a Altman-Z score of -0.66. This is comparable to the rest of the industry: MNOV outperforms 55.56% of its industry peers.
MNOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.66
ROIC/WACCN/A
WACC8.77%
MNOV Yearly LT Debt VS Equity VS FCFMNOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 9.86 indicates that MNOV has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.86, MNOV is in the better half of the industry, outperforming 79.85% of the companies in the same industry.
A Quick Ratio of 9.86 indicates that MNOV has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 9.86, MNOV belongs to the best of the industry, outperforming 80.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.86
Quick Ratio 9.86
MNOV Yearly Current Assets VS Current LiabilitesMNOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MNOV have decreased strongly by -19.05% in the last year.
Looking at the last year, MNOV shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MNOV will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.64% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNOV Yearly Revenue VS EstimatesMNOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2029 2030 2031 2032 200M 400M 600M 800M
MNOV Yearly EPS VS EstimatesMNOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNOV Price Earnings VS Forward Price EarningsMNOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNOV Per share dataMNOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A cheap valuation may be justified as MNOV's earnings are expected to decrease with -21.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNOV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICINOVA INC

NASDAQ:MNOV (12/12/2025, 2:04:47 PM)

1.54

+0.03 (+1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners21.76%
Inst Owner Change-1.02%
Ins Owners2.88%
Ins Owner Change0%
Market Cap75.54M
Revenue(TTM)N/A
Net Income(TTM)-11.05M
Analysts82.5
Price Target7.14 (363.64%)
Short Float %1.19%
Short Ratio0.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.47%
Min EPS beat(2)27.76%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)29.99%
Min EPS beat(4)-6.95%
Max EPS beat(4)57.98%
EPS beat(8)6
Avg EPS beat(8)21.7%
EPS beat(12)10
Avg EPS beat(12)25.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.9
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.22%
ROE -25.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.22%
ROA(5y)-16.33%
ROE(3y)-18.28%
ROE(5y)-17.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.01%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.86
Quick Ratio 9.86
Altman-Z -0.66
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)53.06%
Cap/Depr(5y)91.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-77.39%
EPS Next 2Y-25.47%
EPS Next 3Y-21.05%
EPS Next 5Y11.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.11%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICINOVA INC / MNOV FAQ

What is the ChartMill fundamental rating of MEDICINOVA INC (MNOV) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNOV.


What is the valuation status for MNOV stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICINOVA INC (MNOV). This can be considered as Overvalued.


Can you provide the profitability details for MEDICINOVA INC?

MEDICINOVA INC (MNOV) has a profitability rating of 1 / 10.